



ASX Announcement

27 May 2024

Hydrix signs \$2.3m contract with European medical technology company

Hydrix Limited (Hydrix or the Company) (ASX: **HYD**) is pleased to announce its wholly-owned subsidiary Hydrix Services has entered into a \$2.3m contract with leading European medical company Paul Hartmann AG (**Hartmann**) (**Contract**).

Under the Contract, which commences immediately, Hydrix will provide product development services to Hartmann. The Contract represents the second stage of works that Hydrix will undertake for Hartmann, as part of a multi-stage medical product development program. Hydrix estimates that the stage of works under this Contract will be completed by the end of the 2024 calendar year.

Executive Chairman Gavin Coote commented: *“We are very pleased to partner with such a high-quality company like Hartmann. Winning important projects with leading international medical technology companies demonstrates meaningful progress of Hydrix’s expansion overseas.”*

Ends ----

This announcement is authorised for release by the Board of Directors of Hydrix Limited.

For more information, please contact:

Company Enquiries: Gavin Coote - Executive Chairman
info@hydrix.com
+61 3 9550 8100

Corporate Advisory Enquiries: Matthew Baker – Corporate Adviser, Blue Ocean Equities
MatthewBaker@boeq.com.au
+61 418 830 064

Media Enquires: Rod North - Managing Director, Bourse Communications
rod@boursecommunications.com.au
+61 3 9510 8309

About Hydrix Limited

Hydrix Limited (ASX: HYD) is a powerful product innovation company. Hydrix's purpose is to enhance the health, safety, and well-being of a billion lives. The company leverages its powerful product innovation capability across three business segments: **Services**: design, engineer and deliver world first products and innovation; **Ventures**: invest in high potential medtech clients; and **Medical**: distribute disruptive cardiovascular products.